Smiling African couple doing their online banking and paying bills with a laptop at their kitchen table at home

FSGS and TR-MCD Study

Ages

18 - 75

Location

Phoenix, AZ

Compensation

Up to $1,462
Smiling African couple doing their online banking and paying bills with a laptop at their kitchen table at home

FSGS and TR-MCD Trials in Phoenix

Aventiv Research is currently participating in an FSGS and TR-MCD study at our Phoenix, AZ location. Currently, there are no approved therapies in the US to specifically treat Focal Segmental Glomerulosclerosis (FSGS) or Treatment-Resistant Minimal Change Disease (TR-MCD). Advances in drug therapy are key to treating these diseases in their early stages and preventing further damage.

Enroll Now

FSGS and TR-MCD Clinical Trial

The objective of this study is to evaluate the safety and efficacy of an investigational medication for the treatment of Focal Segmental Glomerulosclerosis (FSGS) and Treatment-Resistant Minimal Change Disease (TR-MCD). You may be eligible to participate in this study if you:

  • Are between 18 and 75 years of age
  • Have Focal Segmental Glomerulosclerosis (FSGS) AND Treatment-Resistant Minimal Change Disease (TR-MCD)

Ready to Volunteer?

Volunteer today to see if you qualify for our FSGS and TR-MCD study. Qualified volunteers may be compensated for time and travel.